barinthuslogo.jpg
Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer
01 oct. 2024 08h00 HE | Barinthus Biotherapeutics
Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer
barinthuslogo.jpg
Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
24 sept. 2024 08h00 HE | Barinthus Biotherapeutics
Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
Barinthus Biotherapeutics Pipeline
Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results
08 août 2024 08h00 HE | Barinthus Biotherapeutics
Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results
barinthuslogo.jpg
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
12 juin 2024 16h01 HE | Barinthus Biotherapeutics
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
barinthuslogo.jpg
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
06 juin 2024 11h15 HE | Barinthus Biotherapeutics
Barinthus Bio presents updated data from two clinical trials in people with chronic hepatitis B at EASL Congress 2024.
barinthuslogo.jpg
Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024
22 mai 2024 08h00 HE | Barinthus Biotherapeutics
Two abstracts highlighting the Company's lead hepatitis B-focused asset will be presented as poster and oral presentations.More mature interim data to be presented at EASL following abstract data cuts...
barinthuslogo.jpg
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
13 mai 2024 08h00 HE | Barinthus Biotherapeutics
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
barinthuslogo.jpg
Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer
01 mai 2024 07h00 HE | Barinthus Biotherapeutics
Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer.
barinthuslogo.jpg
Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections
18 avr. 2024 16h10 HE | Barinthus Biotherapeutics
Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, today announced topline final data from the APOLLO trial (also known as HPV001).
barinthuslogo.jpg
Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments
20 mars 2024 08h15 HE | Barinthus Biotherapeutics
OXFORD, United Kingdom, March 20, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, announced its financial results for the year ended December 31, 2023,...